CASI Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, CASI, CASI Pharmaceuticals Inc, priceseries

CASI Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.86
Close
0.82
High
0.87
Low
0.80
Previous Close
0.85
Daily Price Gain
-0.03
YTD High
0.92
YTD High Date
Feb 18, 2022
YTD Low
0.56
YTD Low Date
Jan 28, 2022
YTD Price Change
-0.03
YTD Gain
-3.53%
52 Week High
2.50
52 Week High Date
Mar 12, 2021
52 Week Low
0.56
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-1.44
52 Week Gain
-63.72%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2017
1.34
Mar 8. 2017
1.44
12 Trading Days
7.77%
Link
LONG
Sep 13. 2017
1.05
Oct 3. 2017
1.75
14 Trading Days
66.80%
Link
LONG
Oct 5. 2017
1.77
Oct 17. 2017
2.35
8 Trading Days
32.83%
Link
LONG
Nov 17. 2017
2.60
Dec 6. 2017
3.40
12 Trading Days
30.78%
Link
LONG
Jan 5. 2018
3.40
Jan 24. 2018
3.92
12 Trading Days
15.23%
Link
LONG
Mar 29. 2018
4.17
Apr 25. 2018
6.65
18 Trading Days
59.48%
Link
LONG
May 1. 2018
7.14
May 16. 2018
7.56
11 Trading Days
5.94%
Link
LONG
Jun 22. 2018
6.28
Jul 10. 2018
7.23
11 Trading Days
15.07%
Link
LONG
Nov 15. 2018
3.52
Dec 6. 2018
3.90
13 Trading Days
10.92%
Link
LONG
Apr 5. 2019
3.16
Apr 9. 2019
3.33
2 Trading Days
5.45%
Link
LONG
Aug 29. 2019
3.17
Sep 13. 2019
3.47
10 Trading Days
9.58%
Link
LONG
Mar 19. 2020
1.90
Mar 23. 2020
2.00
2 Trading Days
5.26%
Link
LONG
Mar 24. 2020
1.80
Mar 31. 2020
1.91
5 Trading Days
6.11%
Link
LONG
May 14. 2020
1.77
Jun 10. 2020
2.54
18 Trading Days
43.29%
Link
LONG
Nov 19. 2020
2.01
Dec 7. 2020
2.37
11 Trading Days
17.94%
Link
LONG
Dec 15. 2020
2.50
Dec 29. 2020
2.82
9 Trading Days
12.82%
Link
LONG
Jan 8. 2021
2.90
Jan 21. 2021
3.12
8 Trading Days
7.58%
Link
LONG
Aug 20. 2021
1.29
Sep 9. 2021
1.59
13 Trading Days
23.25%
Link
Company Information
Stock Symbol
CASI
Exchange
NasdaqCM
Company URL
http://www.casipharmaceuticals.com
Company Phone
240-864-2600
CEO
Ken Keyong Ren
Headquarters
Maryland
Business Address
9620 MEDICAL CENTER DR, STE 300, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000895051
About

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Description

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates include , such as MARQIBO, a microtubule inhibitor for the treatment of adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular b-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading